QuantX Biosciences Closes Oversubscribed $85M Series B Financing

QuantX生物科学公司完成超额认购的8500万美元B轮融资

PRINCETON, N.J. and SHANGHAI, February 9, 2026-- QuantX Biosciences, Inc., a computationally driven drug discovery and development company using advanced modeling and high-performance computing to rapidly design and optimize oral small molecule therapeutics, announced today the close of an oversubscribed $85 million Series B financing co-led by LAV and Sanofi Ventures.

新泽西州普林斯顿和上海，2026年2月9日——QuantX Biosciences, Inc.是一家以计算驱动的药物发现与开发公司，利用先进建模和高性能计算快速设计和优化口服小分子治疗药物。该公司今日宣布完成超额认购的8500万美元B轮融资，本轮融资由LAV和赛诺菲风投共同领投。

Additional investors included Hongshan, and existing investors..

其他投资者包括红杉资本和现有投资者。

The proceeds from this financing will be used to support the clinical development of its best-in-class STAT6 oral small molecule inhibitor and IL-17 oral small molecule inhibitor, in addition to continued discovery efforts for oral therapies in immunology and inflammation.

本次融资所得将用于支持其一流的 STAT6 口服小分子抑制剂和 IL-17 口服小分子抑制剂的临床开发，同时持续推进免疫学和炎症领域口服疗法的发现工作。

“This fundraising is a watershed moment for QuantX as we continue to refine our strong discovery engine, add to our robust pipeline, and advance multiple programs towards human studies,” said Wei Li, Ph.D., Interim Chief Executive Officer of QuantX and a Founding Partner of Creacion Ventures. “In only three years, we’ve assembled a world-class team that’s been successful in not only discovering multiple, new, first-in-class small molecule candidates for diseases with large patient populations, but have also advanced these to IND-enabling studies.”.

“这次融资对QuantX来说是一个分水岭时刻，因为我们继续完善我们强大的发现引擎，充实我们强大的研发管线，并推动多个项目向人体研究迈进，” QuantX临时首席执行官、Creacion Ventures创始合伙人魏立博士表示。“仅仅三年时间，我们就组建了一支世界级的团队，不仅成功发现了多种针对拥有庞大患者群体疾病的新颖、首创小分子候选药物，还成功将这些药物推进到IND申报阶段的研究。”

David Wang, MD, Ph.D., Partner and Senior Managing Director of OrbiMed, added, “The combination of QuantX’s ability to deliver best-in-class assets and the speed by which they’re able to advance these programs makes for a unique value proposition across a variety of therapeutic indications. We look forward to continuing our support of QuantX as they endeavor to transform the standards of care across a range of diseases.”.

奥博资本合伙人兼高级董事总经理王大卫博士补充道：“QuantX能够提供一流的资产，以及他们推进这些项目的速度，使其在各种治疗领域中形成了独特的价值主张。我们期待继续支持QuantX，努力改变多种疾病的治疗标准。”

QuantX Biosciences was co-founded by veteran drug hunters Wayne Tang, Ph.D. and Yax Sun, Ph.D. in 2022. Since its inception, the company has focused on the development of a world class computational drug discovery platform by merging physics-based and statistical modeling, which has resulted in the development of multiple high quality oral small molecule development candidates..

QuantX Biosciences 由资深药物研发专家唐伟博士和孙亚博士于2022年共同创立。自成立以来，该公司专注于通过结合基于物理和统计建模的方法，开发世界级的计算药物发现平台，从而成功推进多个高质量口服小分子候选药物的开发。

Previously incubated by OrbiMed and Creacion Ventures, QuantX has raised $130 million to date.

此前，QuantX由奥博资本和Creacion Ventures孵化，目前已筹集了1.3亿美元。

About QuantX

关于QuantX

QuantX Biosciences is a privately held pharmaceutical company advancing oral small-molecule medicines through a computationally driven drug discovery platform. The company integrates physics-based modeling, statistical methods, and computational chemistry to rapidly design and optimize drug candidates against clinically validated targets.

QuantX Biosciences是一家私营制药公司，通过计算驱动的药物发现平台开发口服小分子药物。该公司整合基于物理学的建模、统计方法和计算化学，以快速设计和优化针对临床验证靶点的候选药物。

QuantX is focused on building a pipeline of differentiated therapies for immune-mediated and inflammatory diseases, with the goal of improving development efficiency and success rates. Headquartered in Princeton, New Jersey, QuantX Biosciences is backed by leading life science investors and a team with deep expertise in drug discovery and development..

QuantX专注于为免疫介导和炎症性疾病构建差异化的治疗管道，旨在提高开发效率和成功率。QuantX Biosciences总部位于新泽西州普林斯顿，得到了领先的生命科学投资者和在药物发现与开发方面拥有深厚专业知识的团队的支持。

Contact:

联系人：

QuantX Contact:

QuantX 联系方式：

Peter Greensmith

彼得·格林史密斯

QuantX Biosciences

康塔克斯生物科学

peter.greensmith@quantbio.com

彼得·格林史密斯@量子生物.com

Media Contact

媒体联系人

Andrew W. Mielach

安德鲁·W·米拉赫

LifeSci Communications

生命科学传播

amielach@lifescicomms.com

amielach@lifescicomms.com